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Hospital wastewater contributes a significant input of pharmaceuticals into municipal wastewater. 
The combination of suspended activated sludge and biofilm processes, as stand-alone or as hybrid 
process (Hybrid biofilm and activated sludge system (HybasTM)) has been suggested as a possible 
solution for hospital wastewater treatment. To investigate the potential of such a hybrid system for 
the removal of pharmaceuticals in hospital wastewater a pilot plant consisting of a series of one 
activated sludge reactor, two HybasTM reactors and one moving bed biofilm reactor (MBBR) has 
been established and adapted during 10 months of continuous operation.  After this adaption phase 
batch and continuous experiments were performed for the determination of degradation of 
pharmaceuticals. Removal of organic matter and?nitrification mainly occurred in the first reactor. 
Most pharmaceuticals were removed significantly. The removal of pharmaceuticals (including x-ray 
contrast media, ß-blockers, analgesics and antibiotics) were fitted to a single first-order kinetics 
degradation function, giving degradation rate constants from 0 to 1.49 h-1, from 0 to 7.78×10-1 h-1 , 
from 0 to 7.86×10-1 h-1 and from 0 to 1.07×10-1 h-1  for first, second, third and fourth reactor 
respectively. Generally, the highest removal rate constants were found in the first and third reactor 
while the lowest were found in the second one. When the removal rate constants were normalized to 
biomass amount, the last reactor (biofilm only) appeared to have the most effective biomass in 
respect of removing pharmaceuticals. In the batch experiment, out of 26 compounds, 16 were 
assessed to degrade more than 20% of the respective pharmaceutical within the HybasTM train. In 
the continuous flow experiments, the measured removals were similar to those estimated from the 
batch experiments, but the concentrations of a few pharmaceuticals appeared to increase during the 
first treatment step. Such increase could be attributed to de-conjugation or formation from other 
metabolites.  
?????????
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Hospitals represent a substantial point source for pharmaceuticals discharged to the municipal sewer 
system and the wastewater from hospitals is usually co-treated together with municipal wastewater 
(Santos et al., 2013; Verlicchi et al., 2010; Thomas et al., 2007). Earlier studies have shown, that 
conventional activated sludge treatment in WWTPs is inefficient for full removal of 
pharmaceuticals (Ternes et al., 2004; Joss et al., 2006). Thus, source-treatment of hospital 
wastewater has been proposed in industrialized and developing countries to decrease the quantity of 
pharmaceuticals discharged to municipal WWTPs (Verlicchi et al.; 2010; 2015; Pauwels and 
Verstraete; 2006). This source-treatment proposal gets more important when it comes to big 
hospital sizes. 
It is mainly due to pathogen-spreading concerns that countries like China and Japan are currently 
treating hospital wastewater based on conventional activated sludge process or MBR (Membrane 
Bioreactor) (Pauwels and Verstraete, 2006; Liu et al., 2010). There are only a few studies on 
hospital wastewater were the removal of pharmaceuticals is described:: Marienhospital 
Gelsenkirchen and Waldbröl (Germany), Isala clinics in Zwolle (The Netherlands), Cantonal 
Hospital of Baden (Switzerland) (Pills, 2012), Ioannina hospital (Greece) (Kosma et al., 2010) and 
Herlev hospital (Denmark) (Nielsen et al., 2013). Processes based on activated sludge are, however, 
not sufficient to ensure high removal of pharmaceuticals, which means that additional post-
treatment is required. Numerous post-treatment processes like activated carbon, ultraviolet 
photolysis, advanced oxidation processes (AOPs), reverse osmosis or nanofiltration can remove 
pharmaceuticals from wastewater (Pauwels and Verstraete, 2006; Joss et al., 2008). In some 
treatments based on membrane bioreactors with sludge (MBR), the systems were accompanied with 
AOPs or ultraviolet photolysis to be effective (Nielsen et al., 2013; Köhler et al., 2012; Kovalova et 
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al., 2013; Kovalova et al., 2012). Fungal fluidized-bed bioreactors were also tested for 
pharmaceuticals removal in hospital wastewater (Cruz-Morató et al., 2014), and presented better 
efficacy than the activated sludge systems. Finally, suspended biofilm systems such as MBBRs 
(Moving Bed Biofilm Reactors) have appeared to directly remove pharmaceuticals from hospital 
wastewater (Escolà Casas et al., 2015).  
Different biofilm technologies have recently appeared as an effective tool to remove micro-
pollutants with the main focus being on porous media biofilm processes i.e., slow sand filter e.g. 
(Bester and Schafer, 2009; Escolà Casas and Bester, 2015; Heberer et al., 2004; Hijosa-Valsero et 
al., 2011; Janzen et al., 2009; Li et al., 2014; Reungoat et al., 2011; Zearley and Summers, 2012). 
Along with such biofilm technologies, MBBR also seemed to be a promising solution to remove 
micro-pollutants, which cannot be removed with activated sludge treatment (Hapeshi et al. 2013; 
Zupanc et al. 2013; Falås et al. 2012; Falås et al. 2013; Escolà Casas and Bester 2015). 
HybasTM is a hybrid process, based on the integrated fixed-film activated sludge technology, where 
polyethylene carriers for biofilm growth are suspended within activated sludge in one reactor 
(Christensson and Welander, 2004; Ødegaard et al., 2014). Such carriers are already in operation for 
nitrification and denitrification processes. In this way, HybasTM contains two separate biomasses: 
one with low sludge age (activated sludge flocks), and one with high-sludge age (attached biofilm 
on MBBR-carriers). This fact allows fast growing biomass to be in the form of activated-sludge 
flocks, while the slow-growing biomass develops on the MBBR carriers. The presence of attached 
biofilm in wastewater treatment systems have shown to improve the activated sludge performance 
for nutrient removal (Debabrata, 2010, Randall and Sen, 1996). Falås et al., 2013 demonstrated that 
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attached biofilm contributes significantly to the overall removal of micro-pollutants in a HybasTM
system.  
According to the literature, HybasTM treatment seems to be a promising option to treat hospital 
wastewater. Therefore, this study tested and evaluated for the first time the performance of a pilot 
HybasTM plant for the removal of pharmaceuticals from mechanically pre-treated hospital 
wastewater. 
??? ????????????? ???????
?????????????????????
A lab-scale treatment line was established to treat a portion of the wastewater produced at the 
oncology section of Aarhus University Hospital. The line consisted of four three liter reactors in 
series (H1, H2, H3 and P). H1 contained only activated sludge, H2 and H3 contained activated 
sludge and biofilm carriers and P was a polishing step containing only biofilm carriers. Each reactor 
(H2, H3 and H4) contained 500 AnoxKaldnes™ K5 carriers (AnoxKaldnes, Lund, Sweden) and 
resulted in a filling ratio of 50%. The set-up is drawn in Figure 1. The mixing was performed using 
aeration and the wastewater was pumped at 0.95 L h-1 flow into the treatment line. Sludge recycling 
rate from the settler to H1 was 100%.  
The raw hospital wastewater was passed through an 80 μm filter from Amiat Water Systems 
(Bochum, Germany) using a monopump (Pump 1) from Seepex (Hillerød, Denmark) into the 
mixing tank (100 L). This equalization tank maintained a temperature between 15°C and 18°C and 
its function was to level out the flow and dynamics in the loading over the day as there was 
regularly low flow during nights in the sewage pipe. Using a peristaltic pump (Pump 2) from 
Watson-Marlow (Ringsted, Denmark) the water was pumped from H0 to H1. The main parameters 
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of the wastewater (pH, oxygen, temperature, COD, DOC, NH4-N, NO2-N and NO3-N) were 
measured regularly. 
It was intended to perform BOD removal and nitrification in H1 and have biofilms operating on low 
BOD loading in H2, H3 and P being more adapted to degrade complex and difficult to degrade 
organic matter that the sludge cannot degrade. It was hypothesised that this might induce an ability 
to degrade pharmaceuticals that are recalcitrant to sludge treatment.   
????????????????????????
The study used two different methodologies to experimentally investigate the system’s capacity to 
degrade pharmaceuticals from hospital wastewater. First, a batch experiment was conducted to test 
which of the spiked compounds could be potentially degraded in the treatment train and to study 
their degradation kinetics. Then, a continuous flow experiment was performed to mimic the real 
performance of the system 
???????????????????????
To work with each reactor of the system as a unit, the flow was stopped by turning off the two 
pumps (See figure 1). The connecting tubes were also blocked with clamps. As not all compounds 
are used in a hospital at all times of the each reactor was spiked with a stock solution containing all 
the target compounds, which achieved nominal concentrations of 14 μg L-1 for the pharmaceuticals 
and 200 μg L-1 for the X-ray contrast media to make sure in all reactors was enough for kinetic 
assessment. After the spiking, from 1 minute to 24 h, 10 mL samples were taken with a glass pipette 
from each reactor. The concentrations of pharmaceuticals were analysed by HPLC-MS and the 
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determined concentrations (resulting from the original plus spiked) were used for further 
assessment). 
??????????????????????????????????
?
A ‘volume of water’ was monitored through the stages of the system considering the hydraulic 
retention time. To exclude concentration variations, the inflow of water from the sewer into the 
equalization tank H0 was stopped (Pump 1; see figure 1) and the reactors received the water from 
H0. The system worked with native concentrations of compounds (as they occurred in the hospital 
wastewater). No additional pharmaceuticals were added. H0 and H1 were sampled three times 
during the first 3 hours of the experiment. For the following stages, the hydraulic flow was pursued 
by sampling in accordance to the hydraulic retention time of the system. Sampling times can be 
seen in Figure 3. 
??????????????
?
The compounds used for calibration as well as for spiking in the batch experiments were obtained 
from diverse suppliers as presented in the supplementary material (S1) along with structures and 
CAS numbers. The selection was based on a Danish priorisation list of pharmaceuticals of concern 
adopted to be run all in one chromatographic method to gain best insights into reactor performance.  
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The following compounds were analysed: 
Antibiotics: Azithromycin, Ciprofloxacin, Clarithromycin, Clindamycin, Erythromycin, 
Sulfadiazine, Sulfamethizole, Sulfamethoxazole, Trimethoprim 
Blood pressure regulators: Atenolol, Metoprolol, Propranolol, Sotalol 
Diverse: Carbamazepine, Diclofenac, Ibuprofen, Phenazone, Tramadol, Citalopram, Venlafaxine 
X-ray contrast media: Diatrizoic acid, Iohexol, Iopromide, Iomeprol, Iopamidol 
And the metabolite Acetyl-Sulfadiazine   
Formic acid and gradient grade methanol were from Merck (Darmstadt, Germany); water was 
obtained from an in-house Millipore apparatus. 
?
???? ????????????????????????????????????
?
The main parameters were measured frequently in the treatment train. Samples for Dissolved 
Organic Carbon (DOC), Chemical Oxygen Demand (COD), ammonium nitrogen (NH4+-N), nitrite 
nitrogen (NO2—N) and nitrate nitrogen (NO3--N) were collected and analysed for all reactors. 
Subsamples of approximately 50mL were filtered with a 0.45μm filter. Samples for DOC were 
preserved in the freezer until analysis, while samples for COD, NH4+-N and NO2--N and NO3--N 
were analysed the same day.  
COD, NH4+-N, NO2-- N and NO3--N concentrations [mg/L] were analysed on a Hach Lange robot 
Rohasys, AP 3800 Multi with the application of Hach Lange cuvette tests for COD (LCK 414), 
NH4+-N (LCK 303/304), NO2-- N (LCK 341) and NO3--N (LCK 339) following the manufacturer’s 
instructions (HACH LANGE GMBH, Düsseldorf, Germany).  
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Sludge from Viby municipal WWTP was used for seeding of the HybasTM plant. The concentration 
of suspended solids was kept between 3.0- 3.5 g/L and fresh sludge was added every two weeks to 
compensate for losses. The suspended solids were determined by filtering through a paper filter 
with 0.45 μm pore width succeeded by drying and weight determination. The reactors were 
operated with 100% sludge recycle thus giving in reality a sludge age of around 20 weeks/140d.  
??????????????????????????
Ten carriers from H2, H3 and P reactors were placed on an aluminum-foil cup, dried overnight at 
105ºC, and weighed. The carriers were then washed in tepid 2M NaOH and cleaned with de-ionized 
water. After washing, the carriers were dried again at 105 ºC overnight and the aluminium cup was 
weighed with and without carriers. Content of biomass on the carriers was calculated as the weight 
difference before and after cleaning of carriers. The biomass content per area was calculated 
knowing that each carrier has a protective surface area of 0.00242 m2. 
?
?
???? ?????????????????????????????????
??????????????????????????????????????
?
After each sampling, the samples were stored in a fridge at 4°C. When the experiment was finished, 
all samples were transported under cooled conditions to the laboratory. Once there, 3.5 mL of 
methanol were added to each 10 mL sample and put to -20?C while waiting for analysis. When 
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analysing, the samples were left to reach room temperature and homogenized. 1.5 mL subsamples 
of each sample were transferred to HPLC vials and centrifuged for 10 minutes at 6000 rpm. 900 μL 
of the aqueous phase were taken with a syringe and transferred to a new HPLC vial. 100 μL of 
internal standard were added to each sample with a glass syringe. Finally, the samples were 
analysed by means of HPLC-MS/MS. Injections of 10 and 50 μL were used for the batch and 
concentration profile experiments correspondingly. 
?
?
?????? ??????????
?
The concentrations of the pharmaceuticals in the hospital wastewater and the treatment reactors 
were quantified by means of HPLC-MS/MS. The HPLC had a dual low-pressure mixing ternary-
gradient system Ultimate 3000 from Dionex. The system operated with a pump of the 3000 series 
(DGP-3600 M), a 3000 TSL autosampler (WPS 3000 TSL) and a column oven and degasser also 
from Dionex 3000. The mass spectrometer model was an API 4000 (ABSciex, Framingham, MA, 
USA). HPLC and MS/MS conditions are stated in the supplementary information (S2). 
?????? ??????????????
?
The concentrations of all the compounds over time in the wastewater were plotted. For each 
experiment, the data was treated in a different way as described in the following lines. 
?????????????????????????
?
Concentrations were plotted for each reactor and compound. Figure 2 shows nine illustrative 
compounds while the remaining compounds are shown in the supplementary material (Figure S1). 
First-order degradation equation (Equation 1) was fitted using GraphPad Prism, with no weighting: 
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Equation 1:  ? ? ???? ? ????
C expresses initial and concentration, k is the removal rate constant, t stands for time. 
The k values of each reactor were used to calculate a removal (%) of each of the compounds within 
the treatment train by using Equation 2: 
Equation 2: 
??
??? ?
??
?? ? ?? ? ??? ? ??? ? ??? ? ???? ? ?? ? ??? ? ???? ? ?? ? ??? ? ???? ? ??? ? ??? ? ???
?
CP and CH0 express the concentrations in the reactors H0 and P [μg/L] correspondingly, ki express 
the removal rate constants [h-1] in the H1, H2, H3 and P reactors. ?i refers to the hydraulic residence 
times [h] of H1, H2, H3 and P reactors while ?i and ?r describe the inflow and recirculation flows 
[L/h] respectively. 
As expressed on Equation 3, the hydraulic residence time for H1, H2 and H3 was the same and can 
be found as the tank volume divided with the sum of inflow and recirculation flows. For the last 
reactor (P), the hydraulic residence time was different than H1-H3 and can be calculated as tank 
volume divided with inflow.  
Equation 3: 
??? ??
???????????
?? ?? ??? ? ???? ? ? ??? ?? ? ??????? ??
???????????
??
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Compounds giving estimated removals over 20% during the treatment system were considered to be 
degradable. 
?
???????????????????????????????????
The concentrations measured during 3 hours in each reactor were represented in a plot. Figure 3 
shows four representative compounds. The removal (%) was calculated by comparing 
concentrations from H0 to H1, H2, H3 and P according to Equation 4:
Equation 4: 
For the degradation evaluation, a compound was considered degradable when the removal (%) after 
the treatment train would be over 20%. This assessment was based on an expanded uncertainty 
(measurements and experimental) of ±10%.  
??? ??????????????????????
????????????????????????????????????????????????
?
The system had operated continuously for 10 months before the experiments were performed. All 
flows and set points of the system were kept constant for the last two months after which the 
experiments were performed. The parameters that characterise the general water treatment 
performance in this period are summed up in Table 1. 
??????????? ? ?? ? ? ??????????????????????????????????????????????????????????? ? ? ???
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Oxygen was never below 2.5 mg/L in H1 (sludge only system) and 4.5 mg/L in H2-H4 (biofilm and 
sludge) thus oxygen concentrations were high enough to support nitrification and aerobic 
biodegradation at the substrate concentrations in the reactors. In the the two-month period before 
the experiments the pH was stable between 7 and 8 except in the last reactor (MBBR).  
Nitrification reached 80-90 % already in H1 that only had sludge, and was complete in H2. This 
shows a high nitrification capacity in the sludge. HybasTM systems are often designed with higher 
loading so the sludge mainly degrades organic material (BOD) but have too low sludge age to 
maintain a high nitrification capacity. Instead biofilm have high nitrifiers density as these bacteria 
are not washed out with the sludge growth. It can be concluded that the system was very low-loaded 
and likely a much higher ammonia load could have been treated. 
In the experimental period the removal of most of the DOC and COD occurred in H1 which is 
consistent with the functional design of the system. In the next stages (H2 to P) a further reduction 
in both parameters is observed (See Table 1). From the COD in and out of the sludge tank H0 an 
operational BOD concentration BODop can be assessed as BODop= COD in – COD out = 244 mg 
O/L.
?
?
???? ????????????????????????????????? ?????????????
The found removal rate constants of the pharmaceuticals were highest in the sludge reactor (H1) 
during the batch experiment. In contrast, for the continuous flow experiments, the same reactor 
(H1) showed negative removals (production) for some compounds. Removals between 0 and 71% 
were observed for reactors H2, H3 and P (Figure 4). 
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???????????????????????
?
Single phase first-order degradation kinetics (Equation 1) was fitted for each pharmaceutical in the 
respective reactors. However, for propranolol, a two-phase first order kinetics approach seemed to 
be a more appropriate fitting (Figure 2) than single phase first-order kinetics. Such fitting is better 
explained in the supplementary information S5. Figure 2 shows nine illustrative compounds while 
the degradation kinetics of the rest of the investigated compounds is shown in the supplementary 
material (S3).  
From these kinetic data, removal rate constants were calculated from the batch experiments (Table 
2). 
?
?
??????????????????????????????????
?
The concentrations of pharmaceuticals during the continuous flow experiment are shown as the 
average concentrations in each reactor. Figure 3 shows nine illustrative compounds. The rest of the 
compounds are presented in the supplementary information (S4). Considering the 17 detected 
compounds in H0, 20% of each of 13 compounds was removed during the treatment. 
During the continuous flow experiment most pharmaceuticals were removed. However, some 
pharmaceuticals presented low or negative removals (i.e. they were produced) (Figures 3 and 4). 
This is a phenomenon that can occur with compounds that are eliminated via urine or faeces in a 
conjugate form. Such conjugates are usually formed during phase II of human metabolism by 
sulfation, acetylation and glucuronidation to increase solubility and to facilitate excretion (Timbrell 
2009). These excreted conjugates can undergo de-conjugation in the course of the sewer or during 
the wastewater treatment by bacterial enzymes. In this way effluent concentrations of the parent 
compound can be bigger than those in the influent. Another study also proposed that the increase of 
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a parent compound could happen via transformation of metabolites from other parent compounds 
(Kovalova et al. 2012).  
The rise of the amount of the parent pharmaceuticals in the effluent or at an intermittent treatment 
stage has formerly been observed in WWTPs (Ternes 1998, Onesios et al. 2009, Falås et al. 2012) 
and in hospital wastewater treatment plants (Kovalova et al. 2012, Cruz-Morató et al. 2014). This 
effect is expected to be even stronger in source treatment systems as hospital wastewater because 
the travel time of conjugates between the source and the treatment is much shorter than in the 
sewers that lead to municipal WWTPs. In Figure 4 the removal observed during the continuous 
flow experiment are compared to the calculated ones from the batch experiments. This comparison 
can be used to discern whether compounds could be potentially biodegraded and to understand each 
of the steps (reactors) in the treatment system. 
The removals found in the batch experiment were comparable to the ones obtained in the 
continuous flow experiment. The difference in removal percentage between batch and experiment 
data corresponded to a standard deviation of ±33%. This fact indicates that such systems could be 
modelled with batch experimental data. On the other side, this study also pointed out how 
measuring inlet and outlet concentrations from treatment systems could hide the actual 
biodegradation process of compounds that are excreted as conjugates as in the case of the first 
reactor (H1), where many compound removals were negative.  
According to Equation 2 the removal over the series of reactors was assessed considering the batch 
reactors and compared to the removals found in the train during continuous flow. It was thus 
predicted that 16 out of 26 compounds were removed with more than 20% within the treatment 
system (Figure 4). From the ki values for the system, kH1 or kH3 were in general the highest removal 
rate constants (Table 2). The fact that H3 had a high removal rate constant was probably related to a 
fairly efficient biomass, even if total biomass in this reactor was less than in the other ones. As H1 
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was the first reactor in the treatment train, most of the total removal was occurring there (Figure 4). 
When correcting the ki values with the amount of biomass per reactor volume (kbio) the most 
efficient reactor appeared to be the polishing MBBR (P). This is an indication that P was actually 
highly adapted to remove micro-pollutants. 
????????????????????????????? ??????
?
Different trends were observed through the different compounds in terms of removal and 
degradation kinetics. 
????????????????????
?
Beta-blockers (atenolol, metoprolol, propranolol and sotalol) could be degraded in the batch 
experiment. For atenolol (Supplementary information S2 and S 3, numerical data in Table 2) a 
removal close to 100% was determined while it was a bit over 20% for the other beta-blockers. 
During the continuous flow experiment atenolol, metoprolol and propranolol were detected in H0 
and degraded later during the treatment train (Metoprolol and Propranolol in Figure 3). The 
degradation rates were fairly matching the estimated ones from the batch experiment. 
Propranolol concentrations were higher in H1 in comparison to H0, such formation of propranolol 
was compensated later by the following reactors removal. This gave an apparent no-removal of 
propranolol when comparing inlet (H0) and outlet (P) concentrations during the continuous flow 
experiment (Figure 3). Propranolol is known to be the only beta-blocker forming conjugates 
(Documed 2014) and, furthermore it was degraded in the batch experiment. Therefore, this apparent 
no-removal was most likely the result of propranolol being formed by de-conjugation at a similar 
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rate than it was being degraded. This finding would also be in agreement with a previous  MBR 
study (Kovalova et al., 2012) that also observed negative removals of propranolol in hospital 
wastewater treatments operating at similar hydraulic retention times. 
Remarkably, atenolol was removed better than the other three beta-blockers. Such high removals 
might be explained by co-metabolism. Unlike metoprolol and sotalol, the biodegradation of atenolol 
has been previously observed and linked to the activity of ammonia-oxidizing bacteria and 
heterotrophs (Sathyamoorthy et al., 2013). This hypothesis of co-metabolism fits the present study 
because, again, unlike metoprolol and sotalol, the degradation of atenolol occurs in parallel to 
ammonia oxidation (Table 2). The removal of atenolol from wastewater has also shown to be higher 
than the removal for other beta-blockers in previous studies on hospital wastewater treatment 
(Nielsen et al., 2013,). 
The degradation of propranolol, metoprolol and sotalol occurred in different tanks than the 
nitrification. This points out that nitrification and degradation of beta-blockers (except perhaps 
atenolol) are independent processes. On the other side, the the removal of atenolol, coinciding with 
nitrification. 
??????????????????????????????? ???????????
?
Iopamidol, iohexol and iomeprol could be degraded following first-order kinetics (Figure 2, 
supplementary material, S2 and S3, numerical data in Table 2), with both, estimated and real 
removal between 60 and 80% (Figure 4). Iopromid and diatrizoic acid were not removed. ICM are 
not metabolized or conjugated in humans (Bourin et al., 1997). Therefore the fact that the data for 
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ICMs from the batch experiment matches the continuous flow results better than most other groups 
of pharmaceuticals investigated might be due to the lack of de-conjugation processes. 
Slow sand-filtration biofilm reactors were able to degrade ICM (Escolà Casas and Bester 2015). 
Also, MBBR were shown to degrade iohexol and diatrizoic acid from wastewater (Hapeshi et al., 
2013). As the hydraulic retention time in the present study was similar to Kovalova et al., (2012), it 
seems that the key to degrade ICM is more likely to rely on the biomass characteristics. In this case 
the determining factor appears to be the presence of different types of biofilm in the treatment 
system that are the common factor (Escolà Casas and Bester 2015; Hapeshi et al., 2013; this study). 
In this study biodegradation was detected in the sludge-only reactor (H1). This result is supporting 
the theory that degradation of ICM is not necessarily only occurring in biofilms but can possibly 
also be performed by sludge organisms. However, selection of microorganisms that grow up in the 
biofilm and seed the sludge might also be of importance. The fact that the system is very low loaded 
in BOD gives a low sludge production and thus the possibility for slow growing microorganisms to 
survive in the sludge without being washed out.  
Iohexol, iomeprol and iopamidol presented the highest kbio in H1 (kH1bio in table 2), which contained 
only sludge, and the lowest kbio in P, which contained only MBBR. The kbio values in H2 and 
H3(kH2bio and kH3bio in table 2) were lower but close to the H1 value. Since the main part of biomass 
in these two tanks was mainly consisting of recirculated sludge from H3 to H1, it makes sense that 
such values do not differ so much from each other (Tables 1 and 2). According to the kbio values, it 
seems that in this set-up, the sludge biomass community was more efficient in removing ICM than 
the MBBR community. 
ICM are usually persistent to conventional WWTP treatment as well as realistic ozone treatment 
(Kovalova et al., 2012, Hapeshi et al., 2013). MBR treatment showed negligible removals of ICM 
from hospital wastewater, except for iopromide which was removed up to 31% (Kovalova et al., 
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2012). Also other hospital wastewater-treatment studies employing MBR (Nielsen et al., 2013) or 
fungal fluidized-bed bioreactor in non-sterile conditions (Cruz-Morató et al., 2014) found low 
removal (ranging from 0 and 44%) for ICM. The direct degradation of the three X-ray contrast 
media by the present treatment train can position HybasTM technology as a solution to remove this 
kind of compounds. 
???????????????????
?
Sulfadiazine, sulfamethoxazole and sulfamethizole as well as the sulfadiazine metabolite (acetyl-
sulfadiazine) are a group related structures (supplementary information, S1) that behaved differently 
during the wastewater treatment. 
During the batch experiment, the concentration of sulfadiazine decreased in H1, H2 and H3 
reactors, while it remained stabled in reactor P. Acetyl-sulfadiazine, its main metabolite, seemed to 
follow the same pattern, degrading fairly fast also in H1, H2 and H3 but not in P. Sulfadiazine is 
mainly conjugated to acetyl-sulfadiazine in humans and excreted as such (Vree et al., 1995). In the 
batch experiments, sulfadiazine and acetyl-sulfadiazine were added, so the de-conjugation of 
sulfadiazine and formation of acetyl-sulfadiazine could not be observed. Instead, it was observed 
that both compounds can be degraded in the HybasTM set-up. 
In the continuous flow experiment sulfadiazine concentrations remained stable, while the 
concentration of acetyl-sulfadiazine increased by 0.6μg L-1 (Figure 3). Thus, the expectations that 
acetyl-sulfadiazine would de-conjugate to form sulfadiazine were not fulfilled. This suggests that 
other interactions might occur between sulfadiazine and sulfadiazine metabolites.  
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The batch experiment showed that both, sulfamethoxazole and sulfamethizole could be degraded by 
the treatment system (Figure 2 and supplementary information S3). In humans, sulfamethoxazole is 
usually also excreted in acetylated form while sulfamethizole is only acetylated in small amounts 
(3%) (Hekster and Vree 1982). When operating the system at continuous flow, 25% of 
sulfamethizole was removed while the other three sulfonamide concentrations appeared to increase 
or stay stable. This is comparable to the results obtained with an MBR by Kovalova et al., (2012) 
but different from Nielsen et al., (2013) who found almost complete removal of sulfonamides by an 
MBR treatment. 
Therefore an explanation for stable concentrations of sulfamethoxazole during the continuous flow 
experiment (Figure 3) could be due to the fact that de-conjugation of acetyl-sulfamethoxazole and 
degradation of sulfamethoxazole would happen at similar rate constants. De-conjugation of acetyl-
sulfamethoxazole has already been observed in previous studies (, Köhler et al., 2012, Kovalova et 
al., 2012) as well as during studies on municipal WWTPs (Onesios et al., 2009). 
Finally, sulfamethizole concentrations diminished by circa 0.7μg L-1. The calculated removal of 
sulfamethizole matched well the experimental removal during the continuous flow experiment. This 
was expected as this compound is not excreted as an acetylated conjugate.  
?????????????????
During the batch experiment, phenazone concentrations decreased following first order kinetics but 
the overall removal was under 20%.. In the present study the pure MBBR reactor (P) showed to be 
the one with the lowest removal. This finding might indicate that the degradation of phenazone is a 
co-metabolic process. Phenazone was not detected during the continuous flow experiment. 
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In the batch experiments the concentrations of tramadol were decreasing but the removal calculated 
with the resulting reaction rate constants was below 20% (not significant). The removal determined 
during the continuous flow experiment agreed to this calcultaion. However, during the batch 
experiment the removal rate constant of tramadol was the lowest in reactor P while during the 
continuous flow experiment reactor P was more effective in removing tramadol. In the previous 
study, on pure MBBR operations, tramadol could not be removed. Also Kovalova et al., (2012) 
found that tramadol was not degraded in an MBR. 
Diclofenac did not degrade in the batch experiment.. The degradation data of diclofenac is 
inconsistent, showing degradation in some systems and to be recalcitrant in others (Onesios et al., 
2009). Further studies regarding the degradation conditions for diclofenac should be conducted in 
the future. 
????????????????????????????????????
?
For batch and continuous flow experiments, venlafaxine removal was under 20%. Previously 
described treatment systems (Nielsen et al., 2013, Kovalova et al., 2012) and data from municipal 
WWTPs (Metcalfe et al., 2010) also described poor removal for this compound. 
The removal of carbamazepine was calculated to be close to 20% during the batch. This 
concentration decrease only occurred in the P reactor during the continuous flow experiment. A 
previous project operating MBBR reactors in series showed similar results for carbamazepine. The 
fact that carbamazepine could be degraded by this MBBR is a small success as carbamazepine is 
usually a very recalcitrant compound in activated sludge WWTP and it has not been degraded in 
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other hospital wastewater-treatment projects (Nielsen et al., 2013, Kovalova et al., 2012, Falås et 
al., 2013, Onesios et al., 2009). 
In the batch experiment citalopram was removed up to a bit less than 20% while during the 
continuous flow experiment the concentration of this compound increased during the H1 treatment, 
stayed stable through H2 and H3 and then decreased during its pass through the P reactor. In a 
previous experiment using MBBR reactors in series citalopram was degraded during the batch 
experiment but it remained stable during the continuous flow experiment. No removal of citalopram 
was also observed in similar projects and WWTPs (Nielsen et al., 2013, Metcalfe et al., 2010). The 
increase of citalopram concentrations in H1 might be due to de-conjugation or formation from other 
metabolites. Such citalopram concentrations were attenuated during through the passage of the P 
reactor.  
?????? ????????????????????????????????
?
The removals of the macrolides erythromycin, clindamycin and clarithromycin were estimated from 
the batch experiments and found to range from 30 to 55% while azithromycin did not degrade. For 
these compounds, the removals in continuous flow experiments were around 40% for erythromycin 
and close to 100% for clindamycin. This data is to some extent in agreement with the previous 
studies by Kovalova et al., (2012) who reported macrolides removals by an MBR between 20 to 
60%. Concerning clindamycin, in two prior studies, it was formed rather than eliminated (Nielsen et 
al., 2013, Kovalova et al., 2012). In contrast, in the present study, clindamycin degraded in both, the 
batch and continuous flow experiments. The key to understand the results discrepancy with 
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previous literature might rely on the sludge/biofilm characteristics of the system that, somehow, 
developed efficient clindamycin degraders.
Regarding other antibiotics, ciprofloxacin was not degraded as reported in Kovalova et al., (2012) 
and Nielsen et al., (2013), where ciprofloxacin degraded 50 and 36% respectively in the MBR. The 
estimated removal of trimethoprim from the first-order kinetics of batch experiments was a bit over 
20%, which agrees well with the removal found in the continuous flow experiment (Figure 2). 
Trimethoprim was produced in H1 but degraded during the following steps of the treatment train. 
??????????????
?
A train of four reactors combining sludge, HybasTM and a polishing MBBR reached similar or better 
removal efficiencies of pharmaceuticals compared to other technologies (i.e activated sludge or 
MBR), particularly when considering specific compounds (like X-ray contrast media). 
The degradation of organic matter and nitrification mainly occurred in the first treatment reactor 
indicating that the system was a low loaded one compared to the systems for treating general 
wastewater. In addition, HybasTM also reached low organic matter values in the outlet through a 
consistent (but small) stepwise removal in the following treatment steps which maintains a low 
loaded biofilm adapted for growing on hardly degradable organic matter. This process results in an 
effluent which is low in DOC and thus more suitable for a cost effective polishing by ozonation 
(Antoniou, 2013). 
The batch experiment helped to assess the potential biodegradation of pharmaceuticals in the 
systems whereas the continuous flow experiment reported actual performance values. Batch and 
continuous flow experimental results matched for several compounds, especially those that are 
excreted unchanged. This means that de-conjugation, bonding to particles or formations from other 
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metabolites are facts that have to be taken in account in such wastewater systems. – It is, however 
expected that the reaction rate constants in full scale will not 100% match those determined in the 
small pilot. For these reasons currently a large pilot with 1m3 tanks is under construction that will 
be able to treat wastewater for a whole hospital department before applying these principles to 
fullscale plants. 
This study also evaluated the effectiveness and role of each reactor. The first three reactors were 
well designed for COD, nitrogen removal and for compounds that might degrade preferably through 
sludge biomass (e.g. X-ray contrast media). On the other hand, the specific activity (kbio) of the 
biomass for micro-pollutants removal was the highest in the last reactor in most cases. Therefore, 
further designs such as up-scaling or addition of ozonation steps should envision a larger polishing 
reactor in order to maximize the removal of recalcitrant pharmaceuticals. Another design option 
could be to operate a high-load HybasTM for BOD removal and a secondary HybasTM for removal of 
organic micro-pollutants. 
The tested combination of sludge, HybasTM and MBBR resulted to be a compact, robust and easy-
to-operate technology that showed to remove not only COD and nitrogen but also some recalcitrant 
micro-pollutants. Therefore, this type of wastewater treatment can be seen as a clever solution for 
hospital wastewater treatment. 
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Table 1: General parameters ± standard deviation for the HybasTM system during a two months 
period including the sampling for both experiments.  
Reactor HRT Biomass pH DOC COD NH4+-N NO2—N NO3--N
  
Sludge
[g/L]
Carriers
[g/m2]          [g/L]
[mgC/L] [mgO/L] [mgN/L] [mgN/L] [mgN/L]
H0 - 0.17 - - 7.6±0.28 59±27 299±209 54±16 0.12±0.13 1.7±1.3 
H1 3 3.12 - - 7.4±0.24 15±3 55±3 7±6 0.97±1.32 50±7 
H2 3 3.12 6.0 2.4 7.3±0.42 16±1 50±10 0.30±0.16 0.06±0.04 56±5 
H3 3 3.12 1.9 0.8 7.4± 0.52 14±2 49±8 0.06±0.05 0.03±0.02 60±9 
P 3 0.04 2.5 1.0 7.8±0.48 12±3 43±12 0.60±0.74 0.02±0.01 49±14 
HRT= Hydraulic retention time [h] 
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Figure 1: Overview of the pilot plant in Aa
  
rhus University Hospital. 
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Figure 2: Concentrations of selected pharmaceuticals during the batch experiment in each reactor 
(H1, H2, H3 and P). Filled lines correspond to a first-order kinetics fitting (Equation 1). 
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Figure 3: Average concentrations for selected compounds in the reactors during the continuous flow 
experiment. The error bars show the SD (n=2 samples for H0 and n=4 for the rest, each sample was 
analysed twice. SD was then derived from 4 measurements in H0 and 8 measurements in the rest of 
the tanks). 
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Figure 4: Removal estimated from the batch experiment (Equation 2) compared to the measured 
removal in the continuous flow experiment by applying Equation 4. *Known to be excreted as 
conjugates, **known metabolites ***suggested to be formed from metabolites of other compounds 
(Kovalova et al. 2012), ****suggested to be bound to faecal particles (Göbel et al. 2007). 
Calculated removal; H0 as initial concentrations (Batch experiment)
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Table 1: General parameters ± standard deviation for the HybasTM system during a two months 
period including the sampling for both experiments.  
 
Reactor HRT Biomass pH DOC COD NH4+-N NO2—N NO3--N 
  
Sludge 
[g/L] 
Carriers 
[g/m2]          [g/L] 
 [mgC/L] [mgO/L] [mgN/L] [mgN/L] [mgN/L] 
H0 - 0.17 - - 7.6±0.28 59±27 299±209 54±16 0.12±0.13 1.7±1.3 
H1 3 3.12 - - 7.4±0.24 15±3 55±3 7±6 0.97±1.32 50±7 
H2 3 3.12 6.0 2.4 7.3±0.42 16±1 50±10 0.30±0.16 0.06±0.04 56±5 
H3 3 3.12 1.9 0.8 7.4± 0.52 14±2 49±8 0.06±0.05 0.03±0.02 60±9 
P 3 0.04 2.5 1.0 7.8±0.48 12±3 43±12 0.60±0.74 0.02±0.01 49±14 
 
HRT= Hydraulic retention time [h] 
  
Table
Click here to download Table: Tables_R2.docx
Ta
bl
e 
2:
 P
ar
am
et
er
s 
fr
om
 c
ur
ve
 fi
tti
ng
 (E
q.
 1
). 
 R
2 
re
la
te
s 
to
 th
e 
fit
 fo
r d
et
er
m
in
in
g 
th
e 
ra
te
 c
on
st
an
t k
, k
i: 
re
ac
to
r r
em
ov
al
 ra
te
 c
on
st
an
t, 
k b
io
M
i: 
re
m
ov
al
 ra
te
 
co
ns
ta
nt
 p
er
 g
ra
m
 o
f b
io
m
as
s 
pe
r l
ite
r (
ac
co
rd
in
g 
to
 T
ab
le
 1
). 
B
ol
d 
va
lu
es
: h
ig
he
st
 k
i o
r k
bi
o a
m
on
g 
th
e 
th
re
e 
re
ac
to
rs
. n
a=
m
at
he
m
at
ic
al
ly
 n
ot
 d
ef
in
ed
. 
 
 
R
ea
ct
or
 H
1 
 
R
ea
ct
or
 H
2 
 
R
ea
ct
or
 H
3 
 
R
ea
ct
or
 H
4 
 
R
2  
k H
1 
k H
1b
io
 
R
2  
k H
2 
k H
2b
io
 
R
2  
k H
3 
k H
3b
io
 
R
2  
k H
4 
k H
4b
io
 
Ac
et
yl
-
su
lfa
di
az
in
e  
0.
93
 
1.
49
×1
00
 
4.
77
×1
0-
1  
0.
99
 
7.
78
×1
0-
1  
1.
41
×1
0-
1  
0.
97
 
7.
86
×1
0-
1  
2.
01
×1
0-
1  
0.
20
 
1.
13
×1
0 
-2
 
1.
09
×1
0-
2  
A
te
no
lo
l 
0.
94
 
1.
14
×1
00
 
3.
66
×1
0-
1  
0.
97
 
6.
82
×1
0-
1  
1.
23
×1
0-
1  
0.
98
 
7.
37
×1
0-
1  
1.
88
×1
0-
1  
0.
90
 
5.
19
×1
0-
2  
4.
99
×1
0-
2  
A
zi
tro
m
yc
in
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
C
ar
ba
m
az
ep
in
e 
0.
44
 
1.
57
×1
0-
2  
5.
03
×1
0-
3  
0.
57
 
1.
81
×1
0-
2  
3.
28
×1
0-
3  
0.
61
 
1.
88
×1
0-
2  
4.
81
×1
0-
3  
0.
54
 
1.
68
×1
0-
2  
1.
62
×1
0-
2  
C
la
rit
hr
om
yc
in
 
0.
86
 
9.
10
×1
0-
2  
2.
92
×1
0-
2  
0.
90
 
7.
62
×1
0-
2  
1.
38
×1
0-
2  
0.
93
 
8.
23
×1
0-
2  
2.
10
×1
0-
2  
0.
75
 
3.
59
×1
0-
2  
3.
45
×1
0-
2  
C
ip
ro
flo
xa
cy
n 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
na
 
n.
a 
na
 
C
ita
lo
pr
am
 
0.
57
 
1.
66
×1
0-
2  
5.
32
×1
0-
3  
0.
71
 
1.
50
×1
0-
2  
2.
72
×1
0-
3  
0.
59
 
1.
52
×1
0-
2  
3.
87
×1
0-
3  
0.
85
 
2.
14
×1
0-
2  
2.
06
×1
0-
2  
C
lin
da
m
yc
in
 
0.
81
 
5.
04
×1
0-
2  
1.
62
×1
0-
2  
0.
92
 
4.
80
×1
0-
2  
8.
69
×1
0-
3  
0.
90
 
3.
45
×1
0-
2  
8.
80
×1
0-
3  
0.
68
 
1.
87
×1
0-
2  
1.
80
×1
0-
2  
D
ia
tri
zo
ic
 a
ci
d 
0.
03
 
4.
61
×1
0-
3  
1.
48
×1
0-
3  
0.
07
 
5.
05
×1
0-
3  
9.
14
×1
0-
4  
0.
09
 
5.
57
×1
0-
3  
1.
42
×1
0-
3  
0.
09
 
5.
41
×1
0-
3  
5.
20
×1
0-
3  
D
ic
lo
fe
na
c 
0.
23
 
6.
67
×1
0-
3  
2.
14
×1
0-
3  
0.
76
 
1.
09
×1
0-
2  
1.
97
×1
0-
3  
0.
69
 
1.
33
×1
0-
2  
3.
39
×1
0-
3  
0.
13
 
3.
48
×1
0-
3  
3.
34
×1
0-
3  
Er
yt
hr
om
yc
in
 
0.
68
 
3.
28
×1
0-
2  
1.
05
×1
0-
2  
0.
84
 
2.
88
×1
0-
2  
5.
22
×1
0-
3  
0.
93
 
3.
32
×1
0-
2  
8.
47
×1
0-
3  
0.
71
 
2.
09
×1
0-
2  
2.
01
×1
0-
2  
Io
he
xo
l 
0.
94
 
2.
40
×1
0-
1  
7.
68
×1
0-
2  
0.
99
 
1.
96
×1
0-
1  
3.
55
×1
0-
2  
0.
99
 
1.
97
×1
0-
1  
5.
03
×1
0-
2  
0.
39
 
1.
29
×1
0-
2  
1.
24
×1
0-
2  
Io
m
ep
ro
l 
0.
91
 
1.
48
×1
0-
1  
4.
73
×1
0-
2  
0.
93
 
1.
34
×1
0-
1  
2.
42
×1
0-
2  
0.
95
 
1.
31
×1
0-
1  
3.
33
×1
0-
2  
0.
32
 
1.
13
×1
0-
2  
1.
08
×1
0-
2  
Io
pa
m
id
ol
 
0.
89
 
2.
03
×1
0-
1  
6.
51
×1
0-
2  
0.
96
 
1.
79
×1
0-
1  
3.
24
×1
0-
2  
0.
97
 
1.
72
×1
0-
1  
4.
39
×1
0-
2  
0.
58
 
2.
22
×1
0-
2  
2.
14
×1
0-
2  
Io
pr
om
id
e 
0.
20
 
1.
16
×1
0-
2  
3.
73
×1
0-
3  
0.
10
 
7.
87
×1
0-
3  
1.
43
×1
0-
3  
0.
15
 
7.
52
×1
0-
3  
1.
92
×1
0-
3  
0.
15
 
6.
94
×1
0-
3  
6.
68
×1
0-
3  
M
et
op
ro
lo
l 
0.
89
 
4.
04
×1
0-
2  
1.
29
×1
0-
2  
0.
98
 
3.
66
×1
0-
2  
6.
64
×1
0-
3  
0.
99
 
3.
79
×1
0-
2  
9.
67
×1
0-
3  
0.
88
 
9.
95
×1
0-
3  
9.
57
×1
0-
3  
Ph
en
an
zo
ne
 
0.
67
 
1.
75
×1
0-
2  
5.
62
×1
0-
3  
0.
93
 
1.
70
×1
0-
2  
3.
08
×1
0-
3  
0.
96
 
1.
80
×1
0-
2  
4.
59
×1
0-
3  
0.
73
 
6.
10
×1
0-
3  
5.
86
×1
0-
3  
Pr
op
ra
no
lo
l 
0.
76
 
2.
46
×1
0-
2  
7.
89
×1
0-
3  
0.
76
 
2.
25
×1
0-
2  
4.
08
×1
0-
3  
0.
73
 
2.
22
×1
0-
2  
5.
66
×1
0-
3  
0.
88
 
2.
15
×1
0-
2  
2.
07
×1
0-
2  
So
ta
lo
l 
0.
76
 
2.
29
×1
0-
2  
7.
34
×1
0-
3  
0.
96
 
2.
20
×1
0-
2  
3.
99
×1
0-
3  
0.
98
 
2.
19
×1
0-
2  
5.
59
×1
0-
3  
0.
88
 
1.
01
×1
0-
2  
9.
72
×1
0-
3  
Su
lfa
di
az
in
e 
0.
71
 
3.
68
×1
0-
2  
1.
18
×1
0-
2  
0.
76
 
3.
40
×1
0-
2  
6.
16
×1
0-
3  
0.
64
 
2.
80
×1
0-
2  
7.
14
×1
0-
3  
0.
00
 
1.
42
×1
0-
3  
1.
36
×1
0-
3  
Su
lfa
m
et
hi
zo
le
 
0.
72
 
3.
05
×1
0-
2  
9.
78
×1
0-
3  
0.
88
 
3.
39
×1
0-
2  
6.
14
×1
0-
3  
0.
94
 
3.
93
×1
0-
2  
1.
00
×1
0-
2  
0.
56
 
8.
95
×1
0-
3  
8.
61
×1
0-
3  
Su
lfa
m
et
ho
xa
zo
le
 
0.
81
 
3.
12
×1
0-
2  
9.
99
×1
0-
3  
0.
93
 
3.
17
×1
0-
2  
5.
75
×1
0-
3  
0.
95
 
2.
99
×1
0-
2  
7.
62
×1
0-
3  
0.
48
 
3.
75
×1
0-
3  
3.
60
×1
0-
3  
Tr
im
et
ho
pr
im
 
0.
74
 
2.
40
×1
0-
2  
7.
68
×1
0-
3  
0.
91
 
2.
98
×1
0-
2  
5.
39
×1
0-
3  
0.
88
 
3.
02
×1
0-
2  
7.
70
×1
0-
3  
0.
57
 
1.
17
×1
0-
2  
1.
12
×1
0-
2  
Tr
am
ad
ol
 
0.
67
 
1.
75
×1
0-
2  
5.
62
×1
0-
3  
0.
93
 
1.
70
×1
0-
2  
3.
08
×1
0-
3  
0.
96
 
1.
80
×1
0-
2  
4.
59
×1
0-
3  
0.
73
 
6.
10
×1
0-
3  
5.
86
×1
0-
3  
Ve
nl
af
ax
in
e 
0.
34
 
7.
87
×1
0-
3  
2.
52
×1
0-
3  
0.
93
 
6.
87
×1
0-
3  
1.
25
×1
0-
3  
0.
86
 
7.
69
×1
0-
3  
1.
96
×1
0-
3  
0.
82
 
6.
48
×1
0-
3  
6.
23
×1
0-
3  
  
 
  
SLUDGE 
MBBR + SLUDGE 
SE
TT
LI
N
G
 
TA
N
K
 
H
1 
H
2 
H
3 
P 
0.
95
 L
 h
-1
 
 
R
ET
U
R
N
 
24
 h
 
M
IX
IN
G
 
TA
N
K
 
H
O
SP
IT
AL
 
H
0 
0.
95
 L
 h
-1
 
MBBR + SLUDGE 
MBBR 
Pu
m
p 
1 Pu
m
p 
2 
Pu
m
p 
3 
Fi
gu
re
C
lic
k 
he
re
 to
 d
ow
nl
oa
d 
Fi
gu
re
: F
ig
ur
e1
_S
ub
m
it_
D
ia
gr
am
 ta
nk
sH
YB
A
S.
pd
f
Supplementary material for on-line publication only
Click here to download Supplementary material for on-line publication only: HYBAS_MS for submission AllSupplementaries.doc
